Stay updated on Anti-CD38 Antibody Trial in CD38+ Malignancies
Sign up to get notified when there's something new on the Anti-CD38 Antibody Trial in CD38+ Malignancies page.

Latest updates to the Anti-CD38 Antibody Trial in CD38+ Malignancies page
- CheckyesterdayChange DetectedThe page now displays a 403 Forbidden error, replacing the normal study details. As a result, users cannot view the NCT01084252 study record or related information.SummaryDifference22%

- Check8 days agoChange DetectedThe list of recruitment sites was updated to add Tel Litwinsky, Israel and remove Qiryat Krinitzi, Israel.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedTel Litwinsky, Israel, 52621 was removed and Qiryat Krinitzi, Israel, 52621 was added to the study's locations. These changes modify the list of participating sites in Israel and may affect where patients can enroll.SummaryDifference0.1%

- Check43 days agoChange DetectedRevision label updated from v3.6.4 to v3.6.5, indicating a minor update to the page or its underlying components. This reflects a version increment rather than a substantive change to content.SummaryDifference0.0%

- Check58 days agoChange DetectedRevision label updated from v3.6.3 to v3.6.4 on the page; this represents a small internal update to the page rendering or documentation rather than a change to study information.SummaryDifference0.0%

- Check79 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3, indicating a deployment/patch update. This change is a backend/metadata update and does not modify the study details or the information presented to users.SummaryDifference0.0%

Stay in the know with updates to Anti-CD38 Antibody Trial in CD38+ Malignancies
Enter your email address, and we'll notify you when there's something new on the Anti-CD38 Antibody Trial in CD38+ Malignancies page.